Literature DB >> 22302097

Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.

Simone Filosto1, Cathleen R Becker, Tzipora Goldkorn.   

Abstract

The EGF receptor (EGFR) and its downstream signaling are implicated in lung cancer development. Therefore, much effort was spent in developing specific tyrosine kinase inhibitors (TKI) that bind to the EGFR ATP-pocket, blocking EGFR phosphorylation/signaling. Clinical use of TKIs is effective in a subset of lung cancers with mutations in the EGFR kinase domain, rendering the receptor highly susceptible to TKIs. However, these benefits are limited, and emergence of additional EGFR mutations usually results in TKI resistance and disease progression. Previously, we showed one mechanism linking cigarette smoke to EGFR-driven lung cancer. Specifically, exposure of lung epithelial cells to cigarette smoke-induced oxidative stress stimulates aberrant EGFR phosphorylation/activation with impaired receptor ubiquitination/degradation. The abnormal stabilization of the activated receptor leads to uncontrolled cell growth and tumorigenesis. Here, we describe for the first time a novel posttranslational mechanism of EGFR resistance to TKIs. Exposure of airway epithelial cells to cigarette smoke causes aberrant phosphorylation/activation of EGFR, resulting in a conformation that is different from that induced by the ligand EGF. Unlike EGF-activated EGFR, cigarette smoke-activated EGFR binds c-Src and caveolin-1 and does not undergo canonical dimerization. Importantly, the cigarette smoke-activated EGFR is not inhibited by TKIs (AG1478; erlotinib; gefitinib); in fact, the cigarette smoke exposure induces TKI-resistance even in the TKI-sensitive EGFR mutants. Our findings show that cigarette smoke exposure stimulates not only aberrant EGFR phosphorylation impairing receptor degradation, but also induces a different EGFR conformation and signaling that are resistant to TKIs. Together, these findings offer new insights into cigarette smoke-induced lung cancer development and TKI resistance. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302097      PMCID: PMC4370319          DOI: 10.1158/1535-7163.MCT-11-0698

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  38 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Cancer. A bull's eye for targeted lung cancer therapy.

Authors:  John D Minna; Adi F Gazdar; Stephen R Sprang; Joachim Herz
Journal:  Science       Date:  2004-06-04       Impact factor: 47.728

Review 3.  Mechanisms of Disease: signal transduction in lung carcinogenesis -- a comparison of smokers and never-smokers.

Authors:  Giannis Mountzios; Pierre Fouret; Jean-Charles Soria
Journal:  Nat Clin Pract Oncol       Date:  2008-07-15

4.  Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.

Authors:  L Girard; S Zöchbauer-Müller; A K Virmani; A F Gazdar; J D Minna
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

Review 5.  EGFR mutations and the terminal respiratory unit.

Authors:  Yasushi Yatabe
Journal:  Cancer Metastasis Rev       Date:  2010-03       Impact factor: 9.264

6.  c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential.

Authors:  Richard Marcotte; Lixin Zhou; Harold Kim; Calvin D Roskelly; William J Muller
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

7.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

8.  Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.

Authors:  Satoshi Watanabe; Junta Tanaka; Takeshi Ota; Rie Kondo; Hiroshi Tanaka; Hiroshi Kagamu; Kosuke Ichikawa; Jun Koshio; Junko Baba; Takao Miyabayashi; Ichiei Narita; Hirohisa Yoshizawa
Journal:  BMC Cancer       Date:  2011-01-01       Impact factor: 4.430

9.  The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants.

Authors:  B M Chung; M Dimri; M George; A L Reddi; G Chen; V Band; H Band
Journal:  Oncogene       Date:  2009-03-23       Impact factor: 9.867

10.  ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

Authors:  S Vicent; J M López-Picazo; G Toledo; M D Lozano; W Torre; C Garcia-Corchón; C Quero; J-C Soria; S Martín-Algarra; R G Manzano; L M Montuenga
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

View more
  39 in total

Review 1.  Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence.

Authors:  Silvio De Flora; Gancho Ganchev; Marietta Iltcheva; Sebastiano La Maestra; Rosanna T Micale; Vernon E Steele; Roumen Balansky
Journal:  Trends Pharmacol Sci       Date:  2015-12-23       Impact factor: 14.819

Review 2.  Lung injury and lung cancer caused by cigarette smoke-induced oxidative stress: Molecular mechanisms and therapeutic opportunities involving the ceramide-generating machinery and epidermal growth factor receptor.

Authors:  Tzipora Goldkorn; Simone Filosto; Samuel Chung
Journal:  Antioxid Redox Signal       Date:  2014-07-01       Impact factor: 8.401

3.  Extreme Trait Whole-Genome Sequencing Identifies PTPRO as a Novel Candidate Gene in Emphysema with Severe Airflow Obstruction.

Authors:  Josiah E Radder; Yingze Zhang; Alyssa D Gregory; Shibing Yu; Neil J Kelly; Joseph K Leader; Naftali Kaminski; Frank C Sciurba; Steven D Shapiro
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405

4.  Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Shaohua Cui; Liwen Xiong; Yuqing Lou; Huangping Shi; Aiqin Gu; Yizhuo Zhao; Tianqing Chu; Huimin Wang; Wei Zhang; Lili Dong; Liyan Jiang
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

Review 5.  The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support.

Authors:  Graham W Warren; Samantha Sobus; Ellen R Gritz
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

6.  The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.

Authors:  Yoon Ki Cha; Ho Yun Lee; Myung-Ju Ahn; Keunchil Park; Jin Seok Ahn; Jong-Mu Sun; Yoon-La Choi; Kyung Soo Lee
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

7.  Cigarette smoke activates the proto-oncogene c-src to promote airway inflammation and lung tissue destruction.

Authors:  Patrick Geraghty; Andrew Hardigan; Robert F Foronjy
Journal:  Am J Respir Cell Mol Biol       Date:  2014-03       Impact factor: 6.914

8.  Src regulates cigarette smoke-induced ceramide generation via neutral sphingomyelinase 2 in the airway epithelium.

Authors:  Samuel Chung; Simon Vu; Simone Filosto; Tzipora Goldkorn
Journal:  Am J Respir Cell Mol Biol       Date:  2015-06       Impact factor: 6.914

Review 9.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

10.  Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells.

Authors:  Simone Filosto; David S Baston; Samuel Chung; Cathleen R Becker; Tzipora Goldkorn
Journal:  Mol Cancer Ther       Date:  2013-05-17       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.